Vous avez cherché: parkinsonpatienter (Danois - Anglais)

bivirkninger som søvnighed og pludselig indsættende søvn er set specielt for parkinsonpatienter.
mirapexin has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with parkinson’s disease.

i kliniske forsøg med længere behandlingstid hos parkinsonpatienter fandtes ikke interaktion med selegilin.
similarly, no interactions between entacapone and selegiline were observed in repeated-dose studies in parkinsonian patients.

høje 3-omd-plasmakoncentrationer er sat i forbindelse med dårligt respons på levodopa hos parkinsonpatienter.
high levels of plasma 3-omd have been associated with poor response to levodopa in parkinson’s disease patients.

hos parkinsonpatienter har malignt neuroleptikasyndrom tendens til at indtræffe, når behandling med dopaminerg-forstærkende medicin afbrydes eller stoppes.
in parkinson`s patients, nms tends to occur when discontinuing or stopping dopaminergic-enhancing medications.

en undersøgelse af parkinsonpatienter bekræftede imidlertid, at der efter seponering af behandlingen ikke forekom nogen signifikant ændring af levodopas farmakokinetik eller af patientens respons på levodopa sammenlignet med niveauerne før behandlingen.
however, a study in parkinson’s patients confirmed that after treatment discontinuation there was no significant change in levodopa pharmacokinetics or in patient response to levodopa compared to pretreatment levels.

derfor bør der udvises forsigtighed, når potente noradrenalin- uptakehæmmere som f.eks. desipramin, maprotilin eller venlafaxin administreres til parkinsonpatienter i behandling med tasmar og levodopapræparater.
therefore, caution should be exercised when potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered to parkinson’s disease patients being treated with tasmar and levodopa preparations.

en analyse af poolede placebokontrollerede kliniske forsøg, omfattende 1.778 parkinsonpatienter i behandling med pramipexol og 1.297 patienter i placebobehandling, viste, at bivirkninger var hyppigt rapporteret i begge grupper.
based on the analysis of pooled placebo-controlled trials, comprising a total of 1,778 parkinson’s disease patients on pramipexole and 1,297 patients on placebo, adverse drug reactions were frequently reported for both groups.

derfor bør der udvises forsigtighed, når potente noradrenalin- uptake - hæmmere som f. eks. desipramin, maprotilin eller venlafaxin administreres til parkinsonpatienter i behandling med tasmar og levodopapræparater.
therefore, caution should be exercised when potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered to parkinson’ s disease patients being treated with tasmar and levodopa preparations.